Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03895827 · ClinicalTrials.gov registry record · NA
Recovery Initiation and Management After Overdose (RIMO) Experiment
A NA study, sponsored by Chestnut Health Systems.
- Completed
- Registry status
- NA
- Development phase
- 251
- Enrollment target
NCT03895827 is a NA study that has completed, run by Chestnut Health Systems. The registered enrollment target is 251 participants.
The verdict
NCT03895827, a NA study, has completed, sponsored by Chestnut Health Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 251 participants
- Enrollment target
Study Summary
This study targets individuals in Chicago who have received naloxone administered by first responders within the past week to reverse an overdose, but who have not entered into MAT. Study participants will be recruited through partnerships with the Chicago Fire Department (CFD) and/or Police Department (CPD); first responders will be trained to seek consent from individuals who are alert and oriented after receiving naloxone for future contacts by research staff as part of the naloxone standard protocol. Those who consent will be contacted and screened for study eligibility ideally within one week of naloxone administration; eligible participants will be randomly assigned either to the control group, i.e., referral to MAT as usual, or to Recovery Initiation and Management after Overdose (RIMO), an assertive linkage and recovery support intervention. This intervention builds on an evidence-based intervention for treatment linkage, monitoring, and recovery support evaluated in 3 prior clinical trials by the study team.
Interventions
- BEHAVIORAL Recovery Initiation and Management after Overdose (RIMO)
- OTHER Passive Referral to Treatment Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2025-06-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03895827
The ClinicalTrials.gov registry entry for NCT03895827 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chestnut Health Systems, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Recovery Initiation and Management after Overdose (RIMO) is the first listed.
NCT03895827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03895827 about?
NCT03895827 is a clinical study titled "Recovery Initiation and Management After Overdose (RIMO) Experiment". This study targets individuals in Chicago who have received naloxone administered by first responders within the past week to reverse an overdose, but who have not entered into MAT. Study participants will be recruited through partnerships with the Chicago Fire Department (CFD) and/or Police Departm...
What is the current status of trial NCT03895827?
This trial is currently completed. It is a NA study. The enrollment target is 251 participants. The study started on 2022-04-01. Estimated completion is 2025-06-26.
What interventions are being tested in trial NCT03895827?
The interventions under investigation include: Recovery Initiation and Management after Overdose (RIMO) (BEHAVIORAL), Passive Referral to Treatment Control (OTHER).
Who is sponsoring clinical trial NCT03895827?
This trial is sponsored by Chestnut Health Systems, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.